- Home
- INZY vs TCMD Comparison
INZY vs TCMD Comparison
Compare INZY & TCMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INZY
- TCMD
- Stock Information
- Founded
- INZY 2015
- TCMD 1995
- Country
- INZY United States
- TCMD United States
- Employees
- INZY N/A
- TCMD N/A
- Industry
- INZY Biotechnology: Pharmaceutical Preparations
- TCMD Medical/Dental Instruments
- Sector
- INZY Health Care
- TCMD Health Care
- Exchange
- INZY Nasdaq
- TCMD Nasdaq
- Market Cap
- INZY 321.4M
- TCMD 344.2M
- IPO Year
- INZY 2020
- TCMD 2016
- Fundamental
- Price
- INZY $3.13
- TCMD $15.66
- Analyst Decision
- INZY Strong Buy
- TCMD Hold
- Analyst Count
- INZY 7
- TCMD 1
- Target Price
- INZY $16.14
- TCMD N/A
- AVG Volume (30 Days)
- INZY 313.3K
- TCMD 266.3K
- Earning Date
- INZY 11-05-2024
- TCMD 11-04-2024
- Dividend Yield
- INZY N/A
- TCMD N/A
- EPS Growth
- INZY N/A
- TCMD N/A
- EPS
- INZY N/A
- TCMD 0.65
- Revenue
- INZY N/A
- TCMD $285,051,000.00
- Revenue This Year
- INZY N/A
- TCMD $8.83
- Revenue Next Year
- INZY N/A
- TCMD $9.86
- P/E Ratio
- INZY N/A
- TCMD $24.24
- Revenue Growth
- INZY N/A
- TCMD 5.31
- 52 Week Low
- INZY $3.08
- TCMD $11.12
- 52 Week High
- INZY $7.80
- TCMD $16.95
- Technical
- Relative Strength Index (RSI)
- INZY 19.15
- TCMD 57.70
- Support Level
- INZY $4.02
- TCMD $14.61
- Resistance Level
- INZY $4.74
- TCMD $16.40
- Average True Range (ATR)
- INZY 0.27
- TCMD 0.69
- MACD
- INZY -0.11
- TCMD 0.11
- Stochastic Oscillator
- INZY 2.65
- TCMD 79.10
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
About TCMD Tactile Systems Technology Inc.
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.